Publication | Closed Access

Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes

ImmunologyPharmacologyMultidrug ResistanceChvp RegimenPharmacotherapyMedicineRefractory Lymphoproliferative SyndromesDrug Resistance